160 related articles for article (PubMed ID: 21521156)
1. Nitroimidazoles as anti-tumor agents.
Liu K; Zhu HL
Anticancer Agents Med Chem; 2011 Sep; 11(7):687-91. PubMed ID: 21521156
[TBL] [Abstract][Full Text] [Related]
2. Bioreductive therapies: an overview of drugs and their mechanisms of action.
Rauth AM; Melo T; Misra V
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.
Hay MP; Lee HH; Wilson WR; Roberts PB; Denny WA
J Med Chem; 1995 May; 38(11):1928-41. PubMed ID: 7783125
[TBL] [Abstract][Full Text] [Related]
4. [Hypoxia: a therapeutic target].
Fernández-Braña M
Clin Transl Oncol; 2005 Dec; 7(11):475-6. PubMed ID: 16373057
[No Abstract] [Full Text] [Related]
5. Synthesis of the enantiomers of the bioreductively-activated cytotoxin RSU-1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro.
Naylor MA; Threadgill MD; Showalter HD; Stratford IJ; Stephens MA; Fielden EM; Adams GE
Drug Des Discov; 1993; 10(3):249-55. PubMed ID: 8268395
[TBL] [Abstract][Full Text] [Related]
6. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.
Scicinski J; Oronsky B; Ning S; Knox S; Peehl D; Kim MM; Langecker P; Fanger G
Redox Biol; 2015 Dec; 6():1-8. PubMed ID: 26164533
[TBL] [Abstract][Full Text] [Related]
7. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
8. Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs.
Fielden EM; Adams GE; Cole S; Naylor MA; O'Neill P; Stephens MA; Stratford IJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):707-11. PubMed ID: 1544842
[TBL] [Abstract][Full Text] [Related]
9. p-(Methylsulfinyl)phenyl nitrogen mustard as a novel bioreductive prodrug selective against hypoxic tumors.
Kwon CH; Blanco DR; Baturay N
J Med Chem; 1992 May; 35(11):2137-9. PubMed ID: 1597864
[No Abstract] [Full Text] [Related]
10. The role of hypoxia-activated prodrugs in cancer therapy.
Denny WA
Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effect of RB 6145 in human tumour cell lines: dependence on hypoxia, extra- and intracellular pH and drug uptake.
Skarsgard LD; Acheson DK; Vinczan A; Wouters BG; Heinrichs BE; Loblaw DA; Minchinton AI; Chaplin DJ
Br J Cancer; 1995 Dec; 72(6):1479-86. PubMed ID: 8519663
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-Activated Prodrugs of PERK Inhibitors.
Liew LP; Singleton DC; Wong WW; Cheng GJ; Jamieson SMF; Hay MP
Chem Asian J; 2019 Apr; 14(8):1238-1248. PubMed ID: 30615821
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
[No Abstract] [Full Text] [Related]
14. Chemical modification of radiation effects.
Phillips TL
Cancer; 1977 Feb; 39(2 Suppl):987-98. PubMed ID: 319901
[TBL] [Abstract][Full Text] [Related]
15. Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole Alkylsulfonamides.
Bonnet M; Hong CR; Wong WW; Liew LP; Shome A; Wang J; Gu Y; Stevenson RJ; Qi W; Anderson RF; Pruijn FB; Wilson WR; Jamieson SMF; Hicks KO; Hay MP
J Med Chem; 2018 Feb; 61(3):1241-1254. PubMed ID: 29253343
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
[TBL] [Abstract][Full Text] [Related]
17. Hypoxic cell sensitization by misonidazole in vivo and in vitro.
McNally NJ; Denekamp J; Sheldon PW; Flockhart IR
Br J Radiol; 1978 Apr; 51(604):317-8. PubMed ID: 647189
[No Abstract] [Full Text] [Related]
18. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
Papadopoulou MV; Ji M; Rao MK; Bloomer WD
Oncol Res; 1996; 8(10-11):425-34. PubMed ID: 9114435
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
Meng F; Evans JW; Bhupathi D; Banica M; Lan L; Lorente G; Duan JX; Cai X; Mowday AM; Guise CP; Maroz A; Anderson RF; Patterson AV; Stachelek GC; Glazer PM; Matteucci MD; Hart CP
Mol Cancer Ther; 2012 Mar; 11(3):740-51. PubMed ID: 22147748
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and toxicology of sensitizers: mechanism studies.
Rauth AM
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1293-300. PubMed ID: 6469753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
